Atossa Therapeutics Inc (ATOS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.52-0.40%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ATOS
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(8.6) + peer(0.2*-0.6) + term(0.0) → 2.88% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 7, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the second quarter ended June 30, 2026 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 8, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the first quarter ended March 31, 2026 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for pu…
Results of Operations and Financial Condition. On March 25, 2026, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the fourth quarter and year ended December 31, 2025 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be…
of this Form 8-K and in Exhibit 99.1 attached hereto regarding the Company’s estimated cash and cash equivalents balance as of December 31, 2025 is preliminary, unaudited and subject to finalization of its full financial results and completion of the Company’s financial statement closing procedures for the fourth quarter and fiscal year ended December 31, 2025. This estimate also does not present all information necessary for an understanding of the Company’s financial condition as of Decembe…
Results of Operations and Financial Condition. On November 12, 2025, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended September 30, 2025 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” fo…
Results of Operations and Financial Condition. On August 12, 2025, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended June 30, 2025 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for purpo…
Results of Operations and Financial Condition. On May 13, 2025, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended March 31, 2025 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for purpose…
Results of Operations and Financial Condition. On March 25, 2025, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the year ended December 31, 2024 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for purpo…
Results of Operations and Financial Condition. On November 12, 2024, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended September 30, 2024 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” fo…
Results of Operations and Financial Condition. On August 12, 2024, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended June 30, 2024 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for purpo…
Results of Operations and Financial Condition. On May 13, 2024, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended March 31, 2024 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for purpose…
Results of Operations and Financial Condition. On April 1, 2024, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the year ended December 31, 2023 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for purpos…
Results of Operations and Financial Condition. On April 1, 2024, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the year ended December 31, 2023 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for purpos…
Results of Operations and Financial Condition. On November 13, 2023, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended September 30, 2023 financial results and a Company update. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. The information in Items 2.02, and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be “ filed ” for purposes of Section…